Chemical formula: C₂₄H₃₄O₅ Molecular mass: 402.241 g/mol PubChem compound: 11750009
Clascoterone interacts in the following cases:
No interaction clinical studies have been performed. The use of clascoterone cream at the same time as other cutaneous medicinal products has not been evaluated.
Since the systemic exposure of clascoterone and its main metabolite cortexolone following cutaneous application is negligible, no interaction with systemic treatments is expected; however caution is advised in concomitant use with glucocorticoid medicinal products.
There are no or a limited amount of data from the use of cutaneous clascoterone in pregnant women. Animal studies have shown reproductive toxicity following subcutaneous administration. Although systemic absorption of cutaneous clascoterone and its main metabolite cortexolone, is negligible, there could be individual factors (e.g. use over large surfaces, prolonged use) that may contribute to an increased systemic exposure. Based on animals studies and its mechanism of action (androgen receptor inhibition), clascoterone can cause fetal harm. Clascoterone is contraindicated during pregnancy.
The patient must be informed and understand the risks related to the use of clascoterone during pregnancy.
It is unknown whether clascoterone/metabolites are excreted in human milk. A risk to the newborns/infants cannot be excluded.
Use of clascoterone is not recommended while breast-feeding or breast-feeding should be discontinued during treatment with clascoterone.
Women of childbearing potential have to use an effective method of contraception during treatment and for at least 10 days after the last dose. No interaction clinical studies have been performed, therefore, an interaction with hormonal contraception cannot be excluded. The pregnancy status should be verified before initiating treatment with clascoterone in women of childbearing potential.
There are no data on the effect of clascoterone on human fertility. Results from animal studies following subcutaneous administration showed no effect on fertility in male or female rats.
Clascoterone has no or negligible influence on the ability to drive and use machines.
The most frequently occurring adverse reactions are local skin reactions such as erythema (11.5%), scaling/dryness (10.0%), pruritus (7.4%) and stinging/burning (4.0%). These reactions were usually self-limiting and resolved during use of clascoterone.
Adverse reactions reported with cutaneous clascoterone in both adult and adolescent (from 12 to <18 years of age) patients, including clinical trials and post-marketing experience, are presented in the table below, according to the MedDRA system organ classification.
The frequency of adverse reactions is defined as follows: very common ≥1/10; common ≥1/100 and to <1/10; uncommon ≥1/1 000 and to <1/100; rare ≥1/10 000 and to <1/1 000; very rare <1/10 000; not known (cannot be estimated from the available data).
Adverse reactions in adult and adolescent (from 12 to <18 years of age) patients:
| System Organ Class | Adverse reaction | Frequency |
| Infections and infestations | Application site folliculitis | Rare |
| Immune system disorders | Hypersensitivity | Rare |
| Nervous system disorders | Headache | Rare |
| Respiratory, thoracic and mediastinal disorders | Oropharyngeal pain | Rare |
| Skin and subcutaneous tissue disorders | Acne Dermatitis contact | Rare |
| General disorders and administration site conditions | Application site pain Application site dryness Application site erythema Application site hypertrichosis | Common |
| Investigations | Adrenocorticotropic hormone (ACTH) stimulation test abnormal* | Common |
* assessed in the dedicated phase 2 study at supratherapeutic dosages, see section below.
Laboratory evidence of hypothalamic-pituitary-adrenal (HPA) axis suppression(i.e., decreased serum cortisol levels at 30 minutes after ACTH stimulation) was observed in the dedicated phase 2 study in 1/20 (5%) of adult and in 2/22 (9%) of adolescent patients under maximal usage conditions to the entire face, shoulders, upper chest and upper back of acne patients, corresponding to mean daily amounts of 11.3 g (adults) and 9.3 g (adolescents). No clinical signs or symptoms of adrenal suppression were observed. Upon discontinuation of treatment the laboratory test results normalised within 4 weeks.
If HPA axis suppression occurs, treatment interruption should be considered.
Among the 444 subjects aged 12 to <18 years enrolled in phase 2 and phase 3 vehicle-controlled studies for acne vulgaris and exposed to clascoterone cream, the overall incidence of adverse reactions was 4/444 (0.9%).
Frequency, type and severity of adverse reactions through week 12 were similar to those in adults as presented in Table 1, which covers both populations.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.